CHRYSALIS BIOTHERAPEUTICS Trademark

Trademark Overview

On Tuesday, July 14, 2020, a trademark application was filed for CHRYSALIS BIOTHERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the CHRYSALIS BIOTHERAPEUTICS trademark a serial number of 90052179. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Friday, November 17, 2023. This trademark is owned by Chrysalis BioTherapeutics, Inc.. The CHRYSALIS BIOTHERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetic foot ulcers; Pharmaceutical preparations for accelerating healing of human tissue; Therapeutic gels intended for topical use on skin and mucous membranes, intended to accelerate the healing of skin surface wounds and diabetic foot ulcers; Pharmaceuticals for the treatment of acute radiation syndrome; Pharmaceuticals for the treatment of COVID-19; Pharmaceutical products for the prevention and treatment of Degenerative Brain Diseases and Traumatic Brain Injury (TBI)
chrysalis biotherapeutics

General Information

Serial Number90052179
Word MarkCHRYSALIS BIOTHERAPEUTICS
Filing DateTuesday, July 14, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateFriday, November 17, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 16, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetic foot ulcers; Pharmaceutical preparations for accelerating healing of human tissue; Therapeutic gels intended for topical use on skin and mucous membranes, intended to accelerate the healing of skin surface wounds and diabetic foot ulcers; Pharmaceuticals for the treatment of acute radiation syndrome; Pharmaceuticals for the treatment of COVID-19; Pharmaceutical products for the prevention and treatment of Degenerative Brain Diseases and Traumatic Brain Injury (TBI)
Pseudo MarkCHRYSALIS BIO THERAPEUTICS
NOT AVAILABLE"BIOTHERAPEUTICS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 11, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameChrysalis BioTherapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressGalveston, TX 77550
Party NameChrysalis BioTherapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressGalveston, TX 77550

Trademark Events

Event DateEvent Description
Friday, July 17, 2020NEW APPLICATION ENTERED
Tuesday, August 11, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, February 4, 2021ASSIGNED TO EXAMINER
Monday, February 8, 2021EXAMINERS AMENDMENT -WRITTEN
Monday, February 8, 2021EXAMINERS AMENDMENT E-MAILED
Monday, February 8, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, February 8, 2021EXAMINER'S AMENDMENT ENTERED
Monday, February 8, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 16, 2021PUBLISHED FOR OPPOSITION
Tuesday, March 16, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, November 11, 2021SOU EXTENSION 1 GRANTED
Tuesday, May 11, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 11, 2021SOU TEAS EXTENSION RECEIVED
Thursday, November 11, 2021SOU EXTENSION 1 FILED
Saturday, November 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 7, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, December 7, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 7, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 9, 2022SOU EXTENSION 2 FILED
Monday, May 9, 2022SOU TEAS EXTENSION RECEIVED
Monday, May 9, 2022SOU EXTENSION 2 GRANTED
Wednesday, May 11, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 4, 2022SOU TEAS EXTENSION RECEIVED
Friday, November 4, 2022SOU EXTENSION 3 FILED
Friday, November 4, 2022SOU EXTENSION 3 GRANTED
Tuesday, November 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 14, 2022ASSIGNED TO EXAMINER
Monday, May 8, 2023SOU TEAS EXTENSION RECEIVED
Monday, May 8, 2023SOU EXTENSION 4 GRANTED
Monday, May 8, 2023SOU EXTENSION 4 FILED
Saturday, November 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 13, 2024TEAS STATEMENT OF USE RECEIVED
Wednesday, May 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 10, 2023SOU TEAS EXTENSION RECEIVED
Friday, November 10, 2023SOU EXTENSION 5 FILED
Friday, November 17, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, November 17, 2023SOU EXTENSION 5 GRANTED

Related Keywords

biotherapeutics chrysalis treatment pharmaceutical preparations skin pharmaceuticals brain intended foot healing ulcers